ANTIBODIES AGAINST CD73 AND USES THEREOF

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding...

Full description

Saved in:
Bibliographic Details
Main Authors JURE-KUNKEL, Maria, SCHWEIZER, Liang, MYERS, JR., Joseph E, KORMAN, Alan J, HATCHER, Sandra V, SEGA, Emanuela, LEI, Ming, LONBERG, Nils, SRINIVASAN, Mohan, BARNHART, Bryan C, HUANG, Haichun, YAMNIUK, Aaron P, HUANG, Richard Y, CHEN, Guodong, CORBETT, Martin J, SACK, John S, HENNING, Karla A, ZHANG, Pingping, GOODENOUGH, Angela
Format Patent
LanguageEnglish
Published 10.05.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
Bibliography:Application Number: US201515520638